Surface Oncology, Inc.

NasdaqCM:SURF Stock Report

Market Cap: US$65.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Surface Oncology Past Earnings Performance

Past criteria checks 0/6

Surface Oncology's earnings have been declining at an average annual rate of -25.3%, while the Biotechs industry saw earnings growing at 23.5% annually. Revenues have been declining at an average rate of 11.1% per year.

Key information

-25.30%

Earnings growth rate

3.65%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-11.06%
Return on equity-188.10%
Net Marginn/a
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Analysis Article • Nov 07

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Shareholders in Surface Oncology, Inc. ( NASDAQ:SURF ) may be thrilled to learn that the analysts have just delivered a...
Analysis Article • Aug 08

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Market forces rained on the parade of Surface Oncology, Inc. ( NASDAQ:SURF ) shareholders today, when the analysts...
Seeking Alpha • Aug 03

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Surface Oncology press release (NASDAQ:SURF): Q2 GAAP EPS of -$0.46 misses by $0.01. As of June 30, 2022, cash, cash equivalents and marketable securities were $156.6 million, compared to $154.1 million on December 31, 2021.
Seeking Alpha • May 25

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

Surface Oncology has been a major drag for investors. There's no bad news, but there's no good news either. Despite having partnerships with big names, the stock does not move up.
Analysis Article • May 11

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

Surface Oncology, Inc. ( NASDAQ:SURF ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Feb 23

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Jan 18

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

SURF is an early-stage cancer therapeutics company with multiple big pharma partnerships. Cathie Wood's ARK owns a large stake. Current beaten-down prices make it attractive.
Analysis Article • Nov 11

Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Oct 24

Surface Oncology: Staying The Course

Today, we revisit a small oncology focused concern called Surface Oncology that has collaboration deals with some well-known drug giants. The company is also advancing is own pipeline which has made some progress since we last looked at in February of this year. A full investment update on Surface Oncology follows in the paragraphs below.
Seeking Alpha • Jul 13

Surface Oncology: A Diverse, But Early Pipeline

Surface Oncology is an early-stage cancer therapeutics company with five assets in development. However, only 3/5 have hit clinical trials and early clinical trial results have been disappointing. Licenses to GSK and Novartis and current enterprise valuation increase attractiveness.
Analysis Article • Jun 07

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Mar 15

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Every investor in Surface Oncology, Inc. ( NASDAQ:SURF ) should be aware of the most powerful shareholder groups...
Analysis Article • Feb 16

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Dec 08

What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?

A look at the shareholders of Surface Oncology, Inc. ( NASDAQ:SURF ) can tell us which group is most powerful. Insiders...

Revenue & Expenses Breakdown

How Surface Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:SURF Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 230-9326-7
31 Mar 230-90240
31 Dec 2230-64250
30 Sep 2230-662635
30 Jun 2231-632633
31 Mar 2231-57260
31 Dec 213-78250
30 Sep 219013270
30 Jun 219017262
31 Mar 218921240
31 Dec 2012659240
30 Sep 2039-24200
30 Jun 2039-25200
31 Mar 2040-28200
31 Dec 1915-55210
30 Sep 1925-44200
30 Jun 1926-44190
31 Mar 1928-35180
31 Dec 1859-7160
30 Sep 1852-18120
30 Jun 1853-15120
31 Mar 1857-13110
31 Dec 1713-45110
30 Sep 1712-3690
31 Dec 167-1740

Quality Earnings: SURF is currently unprofitable.

Growing Profit Margin: SURF is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SURF is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.

Accelerating Growth: Unable to compare SURF's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SURF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-33.7%).

Return on Equity

High ROE: SURF has a negative Return on Equity (-188.1%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/09 13:24
End of Day Share Price 2023/09/07 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Surface Oncology, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael UlzBaird
Joshua SchimmerEvercore ISI
Salveen RichterGoldman Sachs